The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Trial updates in neoadjuvant adjuvant therapies for early-stage NSCLC
Jay Lee, MD, UCLA Health, Los Angeles, CA, discusses the latest advances in targeted therapies in the neoadjuvant setting for early-stage non-small cell lung cancer (NSCLC). Osimertinib and alectinib, which were assessed in the ADAURA (NCT02511106) and ALINA (NCT03456076) trials respectively, have both proven to be efficacious EGFR- and ALK-positive NSCLC. Patients will benefit from having systemic therapy before and after surgery, and the NeoADAURA (NCT04351555) and NAUTIKA1 (NCT04302025) trials will further assess targeted therapies in this setting. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Moderna Therapeutics
Consulting or Advisory Role – AstraZeneca; Bristol Myers Squibb Foundation; Foundation Medicine; Genentech/Roche; Merck; Novartis; Regeneron
Speakers’ Bureau – AstraZeneca; Genentech/Roche
Research Funding – Bristol-Myers Squibb; Genentech/Roche; Novartis
Patents, Royalties, Other Intellectual Property – UCLA Patents
Travel, Accommodations, Expenses – Genentech/Roche; Genentech/Roche
(OPTIONAL) Uncompensated Relationships – Genentech/Roche; Novartis
